Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III randomized trial
Article
Kumar, P, Mehta, MP, Rodrigus, P et al. (2003). Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III randomized trial
. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 57(2), s133. 10.1016/s0360-3016(03)00838-1
Kumar, P, Mehta, MP, Rodrigus, P et al. (2003). Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III randomized trial
. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 57(2), s133. 10.1016/s0360-3016(03)00838-1